Assertio Announces Results Of A Clinical Trial Investigating The Utility Of Rolvedon Injection When Dosed The Same Day Of Chemotherapy For Patients With Early Stage Breast Cancer

BenzingaDec 13 08:03 ET

Express News | Assertio Holdings Inc - Rolvedon Shows 1.8 Days to Neutrophil Count Recovery

ReutersDec 13 08:01 ET

Express News | Assertio Holdings Inc - No New Safety Signals Identified in Rolvedon Trial

ReutersDec 13 08:01 ET

Express News | Assertio Announces Results of Rolvedon® (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study

ReutersDec 13 08:00 ET

Assertio: Schwichtenberg to Identify Synergies, Innovative Strategies, New Rev Streams >ASRT

Dow JonesDec 12 08:02 ET

Assertio Holdings: Schwichtenberg Currently Serves as Chief Comml Officer >ASRT

Dow JonesDec 12 08:02 ET